Benjamin E. Mizukawa

Hematology | Oncology

3333 Burnet Ave
Cincinnati, OH 45229

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose.

CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose.

Journal: Pediatric blood & cancer

Published: February 24, 2026

Development of hematopoietic stem cell-targeted lipid nanoparticles through lipid composition optimization.

Development of hematopoietic stem cell-targeted lipid nanoparticles through lipid composition optimization.

Journal: Experimental hematology

Published: October 14, 2025

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.

Journal: British journal of haematology

Published: June 04, 2024

GPR68 supports AML cells through the calcium/calcineurin pro-survival pathway and confers chemoresistance by mediating glucose metabolic symbiosis.

GPR68 supports AML cells through the calcium/calcineurin pro-survival pathway and confers chemoresistance by mediating glucose metabolic symbiosis.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: May 28, 2024

SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.

SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.

Journal: Cell reports

Published: November 17, 2023

Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy.

Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy.

Journal: Pediatric blood & cancer

Published: September 26, 2022

IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.

IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.

Journal: EMBO molecular medicine

Published: December 22, 2021

Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms.

Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 30, 2021

Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.

Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.

Journal: Leukemia

Published: June 28, 2021

Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.

Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.

Journal: Nature communications

Published: April 14, 2021

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.

Journal: Pediatric blood & cancer

Published: March 19, 2021

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia.

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia.

Journal: Frontiers in oncology

Published: December 16, 2020

Showing 1-12 of 29

Last Updated: 09/26/2026